| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024808 |
| Receipt No. | R000028535 |
| Official scientific title of the study | An exploratory study for examining the effects of PE on relaxation and stress in healthy adults: A Randomized, Double-blind, Placebo-controlled, Crossover Study. |
| Date of disclosure of the study information | 2017/12/18 |
| Last modified on | 2018/02/22 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | An exploratory study for examining the effects of PE on relaxation and stress in healthy adults: A Randomized, Double-blind, Placebo-controlled, Crossover Study. | |
| Title of the study (Brief title) | The effects of PE on relaxation and stress | |
| Region |
|
|
| Condition | |||
| Condition | None | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To examine the effects of PE on relaxation and stress. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Questionnaire of relaxation/stress |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of test food (PE) for a week, then intake of placebo for a week after wash-out period. | |
| Interventions/Control_2 | Intake of placebo for a week, then intake of test food (PE) for a week after wash-out period. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Healthy males and females aged 20 years old or more | |||
| Key exclusion criteria | 1)Subjects who have allergic reaction to drug and food
2)Subjects who have a severe past medical history, acute infection, or mental disorder 3)Subjects who are heavy smokers (more than 20 cigarettes per day) 4) Subjects who are alcohol addicts 5)Subjects who have an extremely irregular eating pattern and work the shift or the graveyard shift 6)Subjects who are pregnant, lactating or expected to be pregnant during the study 7)Subjects who regularly take medicine, food for specified health uses, and/or health food which would affect the result of the study 8)Subjects who are participating in other clinical trials or have participated in other clinical trials within 4 weeks prior to the study 9)Subjects who are judged as unsuitable for the study by the principal investigator for other reasons |
|||
| Target sample size | 24 | |||
| Research contact person | |
| Name of lead principal investigator | Shoichiro Inoue |
| Organization | Otsuka Pharmaceutical Co., Ltd. |
| Division name | Otsu Nutraceuticals Research Institute |
| Address | 3-31-13 Saigawa, Otsu, Shiga 520-0002, Japan |
| TEL | 077-521-8835 |
| Inoue.Shoichiro@otsuka.jp | |
| Public contact | |
| Name of contact person | Toshiyasu Tamura |
| Organization | TES Holdings Co., Ltd. |
| Division name | Division of Clinical Trial, Department of Development for Clinical Trials |
| Address | 6F University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan |
| TEL | 03-6801-8480 |
| Homepage URL | |
| info@tes-h.co.jp | |
| Sponsor | |
| Institute | Otsuka Pharmaceutical Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Otsuka Pharmaceutical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028535 |